Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Collen

Showing results (411-420 of 715) with videos related to

Pageof 72
Sort By:
European Journal of Biochemistry|October 13, 2000
Prostromelysin-1 (proMMP-3) stimulates plasminogen activation by tissue-type plasminogen activatorB Arza, M F Hoylaerts, J Félez, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|January 28, 1998
Oxidized low density lipoproteins in patients with transplant-associated coronary artery diseaseP Holvoet, J M Stassen, J Van Cleemput, et al.
Thrombosis and Haemostasis|February 28, 1984
Dysfibrinogenemia (fibrinogen Dusard) associated with impaired fibrin-enhanced plasminogen activationH R Lijnen, J Soria, C Soria, et al.
European Journal of Biochemistry|November 15, 1988
Structural and functional characterization of mutants of recombinant single-chain urokinase-type plasminogen activator obtained by site-specific mutagenesis of Lys158, Ile159 and Ile160H R Lijnen, L Nelles, B Van Hoef, et al.
Biochemistry|January 13, 2000
Specific proteolysis of human plasminogen by a 24 kDa endopeptidase from a novel Chryseobacterium SpH R Lijnen, B Van Hoef, F Ugwu, et al.
Human Gene Therapy|January 26, 2000
Sustained expression of human apolipoprotein A-I after adenoviral gene transfer in C57BL/6 mice: role of apolipoprotein A-I promoter, apolipoprotein A-I introns, and human apolipoprotein E enhancerB De Geest, S Van Linthout, M Lox, et al.
Thrombosis and Haemostasis|April 26, 2000
Lack of tPA significantly affects antithrombotic therapy by a GPIIb/IIIa antagonist, but not by a thrombin inhibitor in miceH Matsuno, O Kozawa, S Ueshima, et al.
Blood|May 9, 2001
Depletion of circulating alpha(2)-antiplasmin by intravenous plasmin or immunoneutralization reduces focal cerebral ischemic injury in the absence of arterial recanalizationN Nagai, M De Mol, B Van Hoef, et al.
Circulation|March 1, 1986
Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarctionD Collen, H Bounameaux, F De Cock, et al.
Thrombosis and Haemostasis|August 13, 1990
Characterization of domain deletion and/or duplication mutants of a recombinant chimera of tissue-type plasminogen activator and urokinase-type plasminogen activator (rt-PA/u-PA)L Nelles, H R Lijnen, A Van Nuffelen, et al.
Pageof 72

Showing results (411-420 of 715) with videos related to

Sort By:
Pageof 72
European Journal of Biochemistry|October 13, 2000
Prostromelysin-1 (proMMP-3) stimulates plasminogen activation by tissue-type plasminogen activatorB Arza, M F Hoylaerts, J Félez, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|January 28, 1998
Oxidized low density lipoproteins in patients with transplant-associated coronary artery diseaseP Holvoet, J M Stassen, J Van Cleemput, et al.
Thrombosis and Haemostasis|February 28, 1984
Dysfibrinogenemia (fibrinogen Dusard) associated with impaired fibrin-enhanced plasminogen activationH R Lijnen, J Soria, C Soria, et al.
European Journal of Biochemistry|November 15, 1988
Structural and functional characterization of mutants of recombinant single-chain urokinase-type plasminogen activator obtained by site-specific mutagenesis of Lys158, Ile159 and Ile160H R Lijnen, L Nelles, B Van Hoef, et al.
Biochemistry|January 13, 2000
Specific proteolysis of human plasminogen by a 24 kDa endopeptidase from a novel Chryseobacterium SpH R Lijnen, B Van Hoef, F Ugwu, et al.
Human Gene Therapy|January 26, 2000
Sustained expression of human apolipoprotein A-I after adenoviral gene transfer in C57BL/6 mice: role of apolipoprotein A-I promoter, apolipoprotein A-I introns, and human apolipoprotein E enhancerB De Geest, S Van Linthout, M Lox, et al.
Thrombosis and Haemostasis|April 26, 2000
Lack of tPA significantly affects antithrombotic therapy by a GPIIb/IIIa antagonist, but not by a thrombin inhibitor in miceH Matsuno, O Kozawa, S Ueshima, et al.
Blood|May 9, 2001
Depletion of circulating alpha(2)-antiplasmin by intravenous plasmin or immunoneutralization reduces focal cerebral ischemic injury in the absence of arterial recanalizationN Nagai, M De Mol, B Van Hoef, et al.
Circulation|March 1, 1986
Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarctionD Collen, H Bounameaux, F De Cock, et al.
Thrombosis and Haemostasis|August 13, 1990
Characterization of domain deletion and/or duplication mutants of a recombinant chimera of tissue-type plasminogen activator and urokinase-type plasminogen activator (rt-PA/u-PA)L Nelles, H R Lijnen, A Van Nuffelen, et al.
Pageof 72